Discovery of L-791,943:: A potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor

被引：46

作者：

Guay, D ^{[1
]}

Hamel, P ^{[1
]}

Blouin, M ^{[1
]}

Brideau, C ^{[1
]}

Chan, CC ^{[1
]}

Chauret, N ^{[1
]}

Ducharme, Y ^{[1
]}

Huang, Z ^{[1
]}

Girard, M ^{[1
]}

Jones, TR ^{[1
]}

Laliberté, F ^{[1
]}

Masson, P ^{[1
]}

McAuliffe, M ^{[1
]}

Piechuta, H ^{[1
]}

Silva, J ^{[1
]}

Young, RN ^{[1
]}

Girard, Y ^{[1
]}

机构：

[1] Merck Frosst Ctr Therapeut Res, Quebec City, PQ H9R 4P8, Canada

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2002年 / 12卷 / 11期

关键词：

D O I：

10.1016/S0960-894X(02)00190-7

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Structure-activity relationship studies directed toward improving the potency and metabolic stability of CDP-840 (3) resulted in the discovery of L-791,943 (1 In) as a potent (HWB TNF-alpha = 0.67 muM) and orally active phosphodiesterase type 4 (PDE4) inhibitor. This compound, which bears a stable bis-difluoromethoxy catechol and a pendant hexafluorocarbinol, exhibited a long half-life in rat and in squirrel monkey. It is well tolerated in ferret with an emetic threshold greater than 30 mg/kg (po) and was found to be active in the ovalbumin-induced bronchoconstriction model in guinea pig and in the ascaris-induced bronchoconstriction models in sheep and squirrel monkey. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：1457 / 1461

页数：5

共 50 条

[21] Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer
Yao, Wenqing
Zhuo, Jincong
Burns, David M.
Xu, Meizhong
Zhang, Colin
Li, Yun-Long
Qian, Ding-Quan
He, Chunhong
Weng, Lingkai
Shi, Eric
Lin, Qiyan
Agrios, Costas
Burn, Timothy C.
Caulder, Eian
Covington, Maryanne B.
Fridman, Jordan S.
Friedman, Steven
Katiyar, Kamna
Hollis, Gregory
Li, Yanlong
Liu, Changnian
Liu, Xiangdong
Marando, Cindy A.
Newton, Robert
Pan, Max
Scherle, Peggy
Taylor, Nancy
Vaddi, Kris
Wasserman, Zelda R.
Wynn, Richard
Yeleswaram, Swamy
Jalluri, Ravi
Bower, Michael
Zhou, Bing-Bing
Metcalf, Brian
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (04) : 603 - 606
[22] Discovery of a 3-Pyridylacetic Acid Derivative (TAK-100) as a Potent, Selective and Orally Active Dipeptidyl Peptidase IV (DPP-4) Inhibitor
Miyamoto, Yasufumi
Banno, Yoshihiro
Yamashita, Tohru
Fujimoto, Tatsuhiko
Oi, Satoru
Moritoh, Yusuke
Asakawa, Tomoko
Kataoka, Osamu
Yashiro, Hiroaki
Takeuchi, Koji
Suzuki, Nobuhiro
Ikedo, Koji
Kosaka, Takuo
Tsubotani, Shigetoshi
Tani, Akiyoshi
Sasaki, Masako
Funami, Miyuki
Amano, Michiko
Yamamoto, Yoshio
Aertgeerts, Kathleen
Yano, Jason
Maezaki, Hironobu
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (03) : 831 - 850
[23] Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits
MacPherson, LJ
Bayburt, EK
Capparelli, MP
Carroll, BJ
Goldstein, R
Justice, MR
Zhu, LJ
Hu, SI
Melton, RA
Fryer, L
Goldberg, RL
Doughty, JR
Spirito, S
Blancuzzi, V
Wilson, D
OByrne, EM
Ganu, V
Parker, DT
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (16) : 2525 - 2532
[24] New therapy for male erectile dysfunction: The discovery and clinical impact of viagra, a potent, selective and orally active PDE 5 inhibitor.
Terrett, NK
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U256 - U256
[25] STRUCTURE AND ACTIVITY RELATIONSHIPS LEADING TO THE DISCOVERY OF ICI-D2138, A SELECTIVE, POTENT AND ORALLY ACTIVE INHIBITOR OF 5-LIPOXYGENASE
CRAWLEY, GC
BIRD, TGC
BRUNEAU, P
DOWELL, RI
EDWARDS, PN
FOSTER, SJ
GIRODEAU, JM
MCMILLAN, RM
WALKER, ERH
WATERSON, D
[J]. JOURNAL OF LIPID MEDIATORS, 1993, 6 (1-3): : 249 - 257
[26] Discovery of SC110237, a highly potent, selective and orally active FLT3 inhibitor for the treatment of acute myeloid leukemia
Kong, Norman
Gao, Daxin
Yang, Heping
Yu, Yajun
[J]. CANCER RESEARCH, 2015, 75
[27] Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses (vol 8, pg 135, 2017)
Zhou, Zhong-Zhen
Cheng, Yu-Fang
Zou, Zheng-Qiang
Ge, Bing-Chen
Yu, Hui
Huang, Cang
Wang, Hai-Tao
Yang, Xue-Mei
Xuo, Jiang-Ping
[J]. ACS CHEMICAL NEUROSCIENCE, 2018, 9 (07): : 1868 - 1868
[28] ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study
Kubota-Ishida, Natsuki
Kaji, Chizuko
Matsumoto, Shogo
Wakabayashi, Tsubasa
Matsuhira, Takashi
Okura, Iori
Cho, Naoki
Isshiki, Satoshi
Kumura, Ko
Tabata, Yuji
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 962
[29] Discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor
Vo, Elizabeth Donohue
Zhang, Yang W.
Rominger, Dave
Silva, Jillian M.
Zhang, Yang J.
Lee, Greg
Micozzi, John
Reid, Ben
McDonough, Brooke
Hospital, Audrey
Luengo, Juan I.
Lin, Hong
Pitt, Cameron
[J]. CANCER RESEARCH, 2023, 83 (08)
[30] Discovery of SC10914: a highly potent, selective and orally active PARP inhibitor for the treatment of BRCA1/2 deficient cancer
Gao, Daxin
Yang, Heping
Yu, Yajun
Kong, Norman
[J]. CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 →